Keep pulling the thread on Andrew Huberman.
Andrew Huberman believes that mRNA vaccines for cancer represent a transformative and life-saving technology.
Andrew Huberman predicts that within five years, more than half of Americans will be taking GLP-1 drugs, particularly those from communities with high obesity rates.
Andrew Huberman predicts that even with advances from companies like Neuralink, brain-computer interfaces will not be able to double human memory encoding rates within the next 10 years.
Research from Tony Wyss-Coray's lab at Stanford University, which led to the company Alkahest, identified factors in young blood and post-exercise blood that can rejuvenate the brain and body.
A recent UK study of over 80,000 subjects found that brighter days and darker nights are correlated with better mental health outcomes, especially for conditions like OCD, anxiety, and major depression.
Andrew Huberman was told by a source in Washington that government funding for mRNA cancer vaccines was not cut, contrary to some public messaging.
There is bipartisan support to maintain funding for NIH basic research, with a potential 2% increase.
Eli Lilly is actively working to prevent compounding pharmacies from selling its new GLP-1 drug, Retatrutide.
The GLP-1 drug Retatrutide is already being sold by compounding pharmacies and gray market sources before its official release.
Andrew Huberman predicts the FDA-approved drug Sunosi, which treats excessive daytime sleepiness and has performed well in ADHD trials, will become far more popular.
Technology developed at Stanford University enables efficient cooling of the body's core through the palms and soles of the feet, a principle Andrew Huberman believes will be key to future sleep devices.